Sign In
Buy SAGE
$8.68
+0 (+0%)
At Close: Oct 30, 2025
Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?
09:51am, Monday, 23'rd Dec 2024
Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength do
Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
07:00am, Tuesday, 26'th Nov 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), today announced that the Company will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference o
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
12:01pm, Thursday, 21'st Nov 2024
Sage Therapeutics' pipeline setbacks continue as the phase II DIMENSION study on dalzanemdor for treating Huntington's disease fails to meet the primary goal.
After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
10:36am, Wednesday, 20'th Nov 2024
On Wednesday, Sage Therapeutics Inc SAGE revealed topline results from the Phase 2 DIMENSION Study of dalzanemdor (SAGE-718) in participants with cognitive impairment (CI) associated with Huntington'
Sage Therapeutics to end Huntington's disease trial after key therapy fails again
07:34am, Wednesday, 20'th Nov 2024
It was the third failed trial for the therapy, called dalzanemdor, which also failed to meet its goals in a Phase 2 trial as a treatment for mild cognitive impairment and mild dementia in Alzheimer's
Sage Therapeutics scraps development of rare disease drug after it fails mid-stage study
06:58am, Wednesday, 20'th Nov 2024
Sage Therapeutics will stop development of its experimental drug to treat cognitive impairment in patients with Huntington's disease after it failed a mid-stage study, the drug developer said on Wedne
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced topline results from the Phase 2 DIMENSION Study of dalzanemdor (SAGE-718) in participants with cognitive impa
SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
10:40am, Wednesday, 30'th Oct 2024
Sage Therapeutics' third-quarter 2024 earnings miss estimates. Stock falls in after-hours trading.
Sage Therapeutics, Inc. (SAGE) Q3 2024 Earnings Call Transcript
09:35pm, Tuesday, 29'th Oct 2024
Sage Therapeutics, Inc. (NASDAQ:SAGE ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Katie Plante - Manager of Investor Relations Barry E. Greene - Chief Executive
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates
06:20pm, Tuesday, 29'th Oct 2024
Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $1.52. This compares to loss of $2.81 per share a year ago.
NEW YORK, NY / ACCESSWIRE / October 28, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed ag
Contact Levi & Korsinsky by October 28, 2024 Deadline to Join Class Action Against Sage Therapeutics, Inc. (SAGE)
12:30pm, Monday, 28'th Oct 2024
NEW YORK, NY / ACCESSWIRE / October 28, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
Sage Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SAGE
10:10am, Monday, 28'th Oct 2024
LOS ANGELES , Oct. 28, 2024 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of §�
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
10:00am, Monday, 28'th Oct 2024
LOS ANGELES , Oct. 28, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage"
